Answer
Insomnia is very common (≥1 in 10 patients) with ponatinib monotherapy in patients with previously treated CML or Ph+ ALL.
Sources for this answer
- Ponatinib Incyte 30 mg film-coated tabletsIncyte Biosciences UK Ltd · emc · SmPC §4.8 Undesirable effects · Version 5Document updated
Sources checked